Tesamorelin 10mg Research Vial GHRH analogue studied in body composition research
Putting the evidence side by side Here is the blunt comparison: AOD 9604: 2.6 kg weight loss in 12 weeks (best result), failed six clinical trials, development terminated Semaglutide: 15 to 17 percent body weight loss over 68 weeks, FDA approved, thousands of study participants, consistent results across multiple trials There is no way to frame this comparison that puts AOD 9604 on equal footing with semaglutide when it comes to clinical evidence
Deep, cystic acne rather than surface breakouts
After the pharmaceutical development program concluded in 2007, the accumulated safety dataset was submitted in support of a US FDA Generally Recognized as Safe (GRAS) determination for AOD9604 as a dietary ingredient
All stacking should be physician-evaluated for safety and appropriateness
Pineal Peptides (Epitalon, Endoluten) Circadian & Mitochondrial Support Restores melatonin levels, which protects against kidney fibrosis